Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia Journal Article
| Authors: | Chin, K. K.; Valtis, Y.; Derkach, A.; Yisraeli Salman, M.; Boussi, L.; Ciervo, J.; Geyer, M. B.; Park, J. H.; Tallman, M. S.; Glass, J. L.; Goldberg, A. D.; Stein, E. M. |
| Article Title: | Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia |
| Abstract: | The combination of a hypomethylating agent (HMA) and venetoclax (VEN) is approved for adults aged >75 years with newly diagnosed acute myeloid leukemia (AML) as well as those ineligible for intensive chemotherapy (IC). HMA/VEN is increasingly substituted for IC in adults with AML aged <75 years, particularly in those with adverse cytogenetic and molecular features. When patients fail to respond or relapse after HMA/VEN, the utility of salvage IC is largely unknown. We performed a retrospective single-institution study and identified 46 patients who received IC after HMA/VEN, including 24 patients who received HMA/VEN as their first treatment for AML. This population had complete remission (CR)/CR with incomplete count recovery (CRi)/morphologic leukemia-free state rate of 37%, CR/CRi rate of 28%, and a median overall survival (mOS) of 7.2 months (95% confidence interval, 5.0-10.3). Patients who relapsed after an initial response to HMA/VEN and subsequently received IC were more likely to achieve a CR/CRi than those refractory to HMA/VEN (50% vs 19%; P = .04), although there was no statistically significant difference in survival (mOS, 8.8 vs 5.4 months; P = .64). Age >65 years predicted poorer survival (mOS, 4.3 vs 10.6 months; P < .001). IC after HMA/VEN should be further studied and chosen with caution. © 2025 Elsevier B.V., All rights reserved. |
| Journal Title: | Blood Neoplasia |
| Volume: | 1 |
| Issue: | 4 |
| ISSN: | 2950-3280 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-12-01 |
| Start Page: | 100038 |
| Language: | English |
| DOI: | 10.1016/j.bneo.2024.100038 |
| PROVIDER: | scopus |
| PMCID: | PMC12182834 |
| PUBMED: | 40552141 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Eytan Stein -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work